TNF-alpha inhibitors associated with uveal melanoma
the ONA take:
According to new findings reported in the journal Mayo Clinic Proceedings, researchers warn that there may be a correlation between tumor necrosis factor (TNF)-alpha inhibitors and the development of uveal melanoma.
The researchers report three cases of uveal melanoma that occurred after patients were treated with TNF-alpha inhibitors. Two of the patients were treated at Mayo Clinic in Rochester, Minnesota, and the other was treated at Yale-New Haven Hospital in New Haven, Connecticut. All three, two women and one man, were treated for inflammatory disease with TNF-alpha inhibitors.
This class of drugs include adalimumab, certolizumab pegol, etanercept, golimumab, and infliximab, and they are used to treat inflammatory bowel disease, psoriasis, and rheumatoid arthritis. In the cases reported, the two women were treated for inflammatory bowel disease and developed rapidly growing melanocytic tumors within 1 year of TNF-alpha inhibitor initiation.
The male patient was treated for rheumatoid arthritis and developed a uveal melanoma within 16 months of TNF-alpha inhibitor therapy.
The researchers suggest that there is an association between TNF-alpha inhibitors and cutaneous melanoma and recommend that patients planning to initiate TNF-alpha inhibitor therapy have an eye exam before beginning therapy. If patients have preexisting nevi, they should be monitored with eye examinations at regular intervals during therapy.
There may be a correlation between TNF-alpha inhibitors and the development of uveal melanoma.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- High Symptom Burden With Polycythemia Vera Linked to QoL Impairment
- Bioimpedence Spectroscopy Improves Early Detection of Breast Cancer-Related Lymphedema in At-Risk Patients
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Patient Navigation Reduces Delays in Diagnostic Resolution
- Fee-for-service Medicare Plans Linked to Improved Care During Last Year of Life
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|